Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation.
about
From disease to treatment: from rare skeletal disorders to treatments for osteoporosisBiochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities.Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption--implications for osteoclast qualityAntiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis.Clinical and animal research findings in pycnodysostosis and gene mutations of cathepsin K from 1996 to 2011ONO-5334, a cathepsin K inhibitor, improves bone strength by preferentially increasing cortical bone mass in ovariectomized rats.Radiological and biochemical resolution of nutritional rickets with calciumPotential role of odanacatib in the treatment of osteoporosis.Serum and urine bone resorption markers and pharmacokinetics of the cathepsin K inhibitor ONO-5334 after ascending single doses in post menopausal women.Future anti-catabolic therapeutic targets in bone disease.Biochemical markers in preclinical models of osteoporosis.Cathepsin K inhibitors: a novel target for osteoporosis therapy.Molecular analysis of the CTSK gene in a cohort of 33 Brazilian families with pycnodysostosis from a cluster in a Brazilian Northeast region.Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development.Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib.Novel targets for the prevention of osteoporosis - lessons learned from studies of metabolic bone disorders.Cathepsin K osteoporosis trials, pycnodysostosis and mouse deficiency models: Commonalities and differences.Modeling and simulation of bone mineral density response from a phase 2 study of ONO-5334, a new cathepsin K inhibitor, to support dose selection in osteoporosis.Total Hip Arthroplasty after Treatment of an Atypical Subtrochanteric Femoral Fracture in a Patient with Pycnodysostosis.Assay for cross-linked carboxyterminal telopeptide of type I collagen (ICTP) unlike CrossLaps assay reflects increased pathological degradation of type I collagen in rheumatoid arthritis.Salivary type I collagen degradation end-products and related matrix metalloproteinases in periodontitis.Effects of electroacupuncture on bone mass and cathepsin K expression in ovariectomised rats.Population pharmacokinetic and pharmacodynamic modeling of different formulations of ONO-5334, cathepsin K inhibitor, in Caucasian and Japanese postmenopausal females.
P2860
Q26764854-E06404C6-7B42-496E-BEF9-6529FB547AECQ27687777-1E5B5B3F-ED10-454B-BEA9-C139EB4D83CBQ33591699-1BA02607-130A-42DD-8E4D-C408A8D0E076Q33814283-4E304990-8018-4C5D-A86E-54B47B3319D5Q35040136-FA93ACBF-CDFA-4443-8F8C-C3097A0FC7DFQ35062434-6D3A7F2C-28CE-4B15-8257-6D1C6D02A2E8Q35276837-7FE44F82-B40A-4634-BFC1-60BBFD67FD92Q36136239-E8A9E46F-A790-48D7-A12D-BCDF199877AEQ36468123-8E16BFA8-4886-4CFA-BC01-96D41BE1F2A3Q36532578-0383E239-8945-4554-A144-C8B6B4818B12Q36799410-6FBF3BB0-D3B8-40E1-BB4E-9EC730685F52Q37029906-1214F8F5-6764-4B25-A22A-D1ACFCBEC255Q37203586-9F8EFC11-8096-4EE7-BACE-BB3A7EE182E2Q37462448-229F737C-780F-4540-9BCD-E81B7711A37AQ38183262-03581268-F94A-48DF-9F2E-1E49752681D5Q38470745-8B11CBED-11D9-440B-A77D-53D04FC9F000Q38784335-840B8D89-0799-463A-8DCC-03E330CF1868Q39234438-46FE6C6E-988D-4CF4-A2A6-9BB6D89AC1D1Q42109930-F2574CDA-A5DA-4665-A083-9C963A5D3D95Q44578840-01747350-A84A-48F1-8A70-A1065A41FA4CQ46907637-7F67988D-208C-4F2F-8A6E-511B35583357Q47818783-4B865FEF-7408-4300-BFD6-38712E6E3475Q51152617-D2D5E27D-0A12-4A10-A388-C81B05F2DC73
P2860
Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Determination of bone markers ...... cy on bone matrix degradation.
@en
Determination of bone markers ...... cy on bone matrix degradation.
@nl
type
label
Determination of bone markers ...... cy on bone matrix degradation.
@en
Determination of bone markers ...... cy on bone matrix degradation.
@nl
prefLabel
Determination of bone markers ...... cy on bone matrix degradation.
@en
Determination of bone markers ...... cy on bone matrix degradation.
@nl
P2093
P2860
P1476
Determination of bone markers ...... cy on bone matrix degradation.
@en
P2093
A Superti-Furga
J G Edelson
R J Desnick
P2860
P304
P356
10.1359/JBMR.1999.14.11.1902
P577
1999-11-01T00:00:00Z